ArticleThe clinical respiratory journal2026
Integrated Proteomic and scRNA-Seq Analysis Reveals Pyroptosis-Related Subtypes in Lung Adenocarcinoma.
Article in The clinical respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPyroptosis is a recently identified form of programmed cell death that plays an important role in cancer initiation and progression. However, the function of pyroptosis in lung adenocarcinoma (LUAD) remains unclear. The study integrated proteomic and single-cell RNA sequence (scRNA-seq) data to investigate the potential role of pyroptosis-related proteins (PRPs) in the tumor microenvironment (TME) and their associations with tumor immunity, prognosis, and therapeutic response.
methodsA comprehensive proteomic analysis was conducted on 103 lung adenocarcinoma patients. We integrated scRNA-seq data with bioinformatics analyses to evaluate prognostic and immunological characteristics. Unsupervised clustering based on the PRP expression identified three subtypes. We then used gene set enrichment analysis (GSEA) to assess biological functions. We applied TME and CIBERSORT algorithms to analyze immune cell infiltration. Next, we performed functional enrichment, immune infiltration, and cell-cell communication analyses using scRNA-seq data grouped according to the proteomic subtypes. We constructed a PRP-related prognostic signature using least absolute shrinkage and selection operator (LASSO)-Cox regression analysis. Finally, we validated the expression and functional significance of selected proteins by immunohistochemistry, Western blotting, quantitative PCR, and in vitro loss-of-function assays.
resultsWe identified multiple PRPs that correlated with clinicopathologic characteristics, patient prognosis, and immune infiltration patterns in the TME. We further identified three distinct molecular subtypes, including lipid metabolism, signaling transduction, and immune activation. Among these subtypes, the lipid metabolism subtype showed the best prognosis. ScRNA-seq analysis further supported the immune characteristics of three subtypes and revealed distinct cellular interaction networks and ligand-receptor pairs. We also established and validated a PRP-related prognostic score that effectively predicted overall survival in patients with LUAD. In addition, the PRP score was significantly associated with tumor immune status and sensitivity to chemotherapeutic agents.
conclusionOur integrated analysis of proteomic and scRNA-seq data demonstrated that PRPs are closely associated with the tumor-immune-stromal microenvironment, clinicopathological features, and prognosis in LUAD. These findings improve our understanding of the biological roles of PRPs in LUAD and may provide new strategies for prognostic evaluation and immunotherapy development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.